HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
BHP Shares Fall as Jansen Potash Project Costs Surge 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
NEW YORK, Dec. 01, 2015 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Osiris Therapeutics, Inc. (NASDAQ:OSIR) securities between May 12, 2014 and November 20, 2015.
Click here to learn about the case: http://docs.wongesq.com/OSIR-Info-Request-Form-1014. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Osiris improperly recognized revenue under contracts it had with its distributors; (2) Osiris’ disclosure controls and procedures were not effective as of December 31, 2014, March 31, 2015, and June 30, 2015; and (3) as a result, defendants’ statements about Osiris’ business and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Osiris Therapeutics you have until January 22, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/OSIR-Info-Request-Form-1014.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
